StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRXFree Report) in a research report report published on Thursday. The firm issued a sell rating on the stock.

Separately, Benchmark restated a hold rating on shares of VolitionRx in a report on Friday, August 16th.

Check Out Our Latest Analysis on VolitionRx

VolitionRx Trading Up 16.2 %

Shares of VNRX stock opened at $0.88 on Thursday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The firm’s 50 day moving average is $0.64 and its 200-day moving average is $0.69. The firm has a market capitalization of $81.32 million, a price-to-earnings ratio of -1.92 and a beta of 1.09.

VolitionRx (NYSE:VNRXGet Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.34 million. On average, equities research analysts forecast that VolitionRx will post -0.31 earnings per share for the current fiscal year.

Insider Activity at VolitionRx

In other news, Director Guy Archibald Innes bought 150,000 shares of the stock in a transaction on Tuesday, August 20th. The stock was purchased at an average price of $0.67 per share, with a total value of $100,500.00. Following the completion of the purchase, the director now owns 406,683 shares of the company’s stock, valued at approximately $272,477.61. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 12.80% of the stock is currently owned by company insiders.

VolitionRx Company Profile

(Get Free Report)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

Featured Stories

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.